OM
ONCT

Opaleye Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Opaleye Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,727
Closed -$331K – 68
2020
Q3 		$331K Buy
+9,727
New +$477K 0.06% 51

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management's ONCT Position: Q4 2020 in Review

Opaleye Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2020, closing a stake of 9,727 shares — an estimated $331K sold.

Opaleye Management first reported a position in ONCT in Q3 2020 and held it in 1 quarter. The position peaked at $331K in Q3 2020. 52 funds tracked by Wall St. Rank hold ONCT as of Q4 2020.

  • Opaleye Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Opaleye Management sold 9,727 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $331K.
  • Opaleye Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Opaleye Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $331K in Q3 2020.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Opaleye Management's 13F filing for Q4 2020, filed 12 Feb 2021.